Loading...

immatics biotechnologies GmbH

IMTXW•NASDAQ
Healthcare
Biotechnology
$0.001
$-0.00(-88.46%)

immatics biotechnologies GmbH (IMTXW) Stock Overview

Explore immatics biotechnologies GmbH’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.3/100

Key Financials

Market Cap72.9K
P/E Ratio-29.57
EPS (TTM)N/A
ROE-0.05%
Fundamental Analysis

AI Price Forecasts

1 Week$0.03
1 Month$-0.84
3 Months$0.97
1 Year Target$1.40

IMTXW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of immatics biotechnologies GmbH (IMTXW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 37.31, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.40.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -29.57 and a market capitalization of 72.9K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

37.31RSI (14)
0.00MACD
16.20ADX
Stats data is not available for IMTXWStats details for IMTXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for IMTXWAnalyst Recommendations details for IMTXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

CEO

Harpreet Singh

Employees

554

Headquarters

Paul-Ehrlich-Strasse 15, Tübingen

Founded

2020

Frequently Asked Questions

;